Elkedonia: Antidepressants that act downstream of neurotransmitters

Argobio-founded Elkedonia is investigating a first-in-class intracellular target to treat neuropsychiatric disorders, starting with treatment-resistant depression.

The company’s approach is rooted in translational neuroscience research led by Jocelyne Caboche, director of research at the National Center for Scientific Research (CNRS) at Sorbonne University. ...